Drug Discovery

Drug Repurposing Hypotheses: From Signal to Testable Mechanism

Published 2026-08-22 · Updated 2026-08-22

Answer in brief

Use Drug Repurposing Hypotheses to decide which existing compound-disease pairing deserves mechanistic and validation review before the next expensive commitment. Build the comparison around known targets, exposure, safety, disease mechanism, clinical context, confounding, and competitive evidence and ask what would overturn the preferred route; the earliest useful challenge is: predict a target- or pathway-specific response distinguishable from general associations. Stop at a provisional decision and preserve the remaining validation boundary.

Evidence status: Decision-method guide; not a completed investigation or final validation.

The decision this guide supports

which existing compound-disease pairing deserves mechanistic and validation review

Why the problem is difficult

The article-specific identification challenge is whether the question “which existing compound-disease pairing deserves mechanistic and validation review” can be resolved using known targets, exposure, safety, disease mechanism, clinical context, confounding, and competitive evidence, rather than merely restated in new language.

A falsifier-first workflow

  • Define the decision precisely: which existing compound-disease pairing deserves mechanistic and validation review.
  • Build a source and data ledger around known targets, exposure, safety, disease mechanism, clinical context, confounding, and competitive evidence.
  • Compare the inherited route with a mechanistically distinct alternative and a constraint-based null.
  • Actively search for the strongest counterevidence relevant to this decision, including boundary cases and prior failures.
  • Run the lowest-cost discriminating challenge: predict a target- or pathway-specific response distinguishable from general associations.
  • Record pursue, reframe, or stop, the confidence level, the evidence ceiling, and who owns downstream validation.

Decision criteria

  • Decision impact: would the result materially change the choice about which existing compound-disease pairing deserves mechanistic and validation review?
  • Evidence fit: does the available evidence—known targets, exposure, safety, disease mechanism, clinical context, confounding, and competitive evidence—directly address the decision rather than merely correlate with it?
  • Discrimination: does the preferred route predict an outcome a credible alternative does not?
  • Robustness: does the ranking survive the challenge “predict a target- or pathway-specific response distinguishable from general associations”?
  • Validation boundary: is the conclusion no stronger than the available sources, data and computation?

Supporting evidence

known targets, exposure, safety, disease mechanism, clinical context, confounding, and competitive evidence

Counterevidence

For this decision, a result from “predict a target- or pathway-specific response distinguishable from general associations” that reverses or flattens the ranking must remain visible even when it is commercially inconvenient.

Computation

Here computation earns its place only if it changes the choice about which existing compound-disease pairing deserves mechanistic and validation review or exposes why the available evidence cannot resolve it.

Fastest falsifier

predict a target- or pathway-specific response distinguishable from general associations

When to stop or reframe

A decision-specific stop trigger is failure of the challenge “predict a target- or pathway-specific response distinguishable from general associations” without an independently supported alternative mechanism.

Evidence ceiling

Observational or text-mined associations do not establish efficacy.

Sources and starting points

  • Open Targets Platform — Integrated public evidence connecting therapeutic targets and diseases.
  • ChEMBL — Curated bioactivity information for compounds, assays, and targets.
  • ClinicalTrials.gov — Official registry and results database for clinical studies; registry records are not proof of efficacy.
  • PubMed — Primary biomedical literature discovery; individual studies require direct appraisal.
  • UniProt — Additional authoritative starting point selected for this decision area; applicability must be checked against the precise question.
  • AlphaFold Protein Structure Database — Additional authoritative starting point selected for this decision area; applicability must be checked against the precise question.

Continue the decision journey

  1. Drug Target Prioritization: A Falsifier-First Framework
  2. Target Identification vs Target Validation in Drug Discovery
  3. What Counts as Evidence for Drug Target Validation?
  4. Map the Translational Gap Before Advancing a Drug Program

Explore the full topic hub · Editorial standard · Scientific Oracle consulting

Frequently asked questions

What decision does “Drug Repurposing Hypotheses: From Signal to Testable Mechanism” help make?
It supports a bounded decision about which existing compound-disease pairing deserves mechanistic and validation review. The framework keeps alternatives, evidence, counterevidence, uncertainty, and the fastest falsification test visible.
What is the fastest useful test?
predict a target- or pathway-specific response distinguishable from general associations
Can computation validate the final scientific claim?
No. Observational or text-mined associations do not establish efficacy. Computation can prioritize and eliminate directions; final validation remains with the appropriate domain methods and accountable specialists.
When should the project stop or reframe?
Stop or reframe when the target-disease link is not robust, the mechanism lacks a discriminating prediction, tractability depends on unsupported assumptions, public data contradict the thesis, or the next credible validation belongs in a qualified experimental program.